Champions Oncology

LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours

Retrieved on: 
Tuesday, March 21, 2023
GMP, Learning, Good, ICIS, Partnership, Good manufacturing practice, Immunomodulation, NK, Research, Lift, CD8, Patient, Immune system, TME, CD4, Lymphocyte, Champions Oncology, Vaccine, Pharmaceutical industry

New data released today highlight that IMANp demonstrates a dual mechanism of action, exhibiting unparalleled direct cytotoxicity in combination with exquisite orchestration of the host immune system.

Key Points: 
  • New data released today highlight that IMANp demonstrates a dual mechanism of action, exhibiting unparalleled direct cytotoxicity in combination with exquisite orchestration of the host immune system.
  • The presence of IMANp promoted unprecedented recruitment of host immune cells into solid tumour preclinical models, as well as their activation, which correlated with enhanced tumour cell killing.
  • Furthermore, enhanced proliferation and IFN-γ were observed from tumour infiltrating lymphocytes following co-culture with IMANp.
  • To further consolidate the preclinical data demonstrating cytotoxicity and immunomodulation by IMANp, we have generated successful functional proof of concept data for iPSC-derived and gene engineered IMANp products.

LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours

Retrieved on: 
Tuesday, March 21, 2023
GMP, Learning, Good, ICIS, Partnership, Good manufacturing practice, Immunomodulation, NK, Research, Lift, CD8, Patient, Immune system, TME, CD4, Lymphocyte, Champions Oncology, Vaccine, Pharmaceutical industry

New data released today highlight that IMANp demonstrates a dual mechanism of action, exhibiting unparalleled direct cytotoxicity in combination with exquisite orchestration of the host immune system.

Key Points: 
  • New data released today highlight that IMANp demonstrates a dual mechanism of action, exhibiting unparalleled direct cytotoxicity in combination with exquisite orchestration of the host immune system.
  • The presence of IMANp promoted unprecedented recruitment of host immune cells into solid tumour preclinical models, as well as their activation, which correlated with enhanced tumour cell killing.
  • Furthermore, enhanced proliferation and IFN-γ were observed from tumour infiltrating lymphocytes following co-culture with IMANp.
  • To further consolidate the preclinical data demonstrating cytotoxicity and immunomodulation by IMANp, we have generated successful functional proof of concept data for iPSC-derived and gene engineered IMANp products.

Jyoti Mundra, PhD, appointed as new Chief Business Officer at MEDSIR

Retrieved on: 
Thursday, September 22, 2022
NYU Langone Health, Champions Oncology, Molecular biology, Research, Acquisition, Growth, Rutgers University, Sinclair Research, Business, CRO, Jyoti, Adam, Doctor of Philosophy, Drug development, Hospital, Business development, Management, Pharmaceutical industry, Biochemistry

BARCELONA, Spain, Sept. 22, 2022 /PRNewswire/ -- MEDSIR , an international company specialized in the strategic design of clinical trials is pleased to announcethe appointment of Jyoti Mundra, PhD, as Chief Business Officer.

Key Points: 
  • BARCELONA, Spain, Sept. 22, 2022 /PRNewswire/ -- MEDSIR , an international company specialized in the strategic design of clinical trials is pleased to announcethe appointment of Jyoti Mundra, PhD, as Chief Business Officer.
  • In her role, Jyoti will help accelerate the growth of MEDSIR while enhancing MEDSIR's presence and business in North America.
  • She will be leading global business and marketing team to provide clinical solutions to biopharma companies and build a network with hospitals and institutions.
  • Prior to joining MEDSIR , Jyoti served as a Director of Business Development at Sinclair Research and helped achieve hypergrowth leading to an acquisition by Altasciences.

LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda

Retrieved on: 
Wednesday, April 6, 2022
Cell, Human, 2D, Partnership, Immunotherapy, Death, Lift, Clinical trial, Mouse, IND, Survival, Biotechnology, Research, Cancer, Champions Oncology, CEO, NSCLC, Epithelium, Organoid, MD, Neoplasm, Safety, SC, Cisplatin, Neutrophil, Haplogroup N1a (mtDNA), Pancreatic cancer, Patient, List, Large-cell lung carcinoma, Medical imaging, Pembrolizumab

A Tumouroid is when cells extracted from a patients tumour are cultured into a suspended 3D model to create 3D tumour fragments.

Key Points: 
  • A Tumouroid is when cells extracted from a patients tumour are cultured into a suspended 3D model to create 3D tumour fragments.
  • Furthermore, N-LIfT showed complete superiority to Keytruda, a gold-standard treatment for NSCLC, in Tumouroid reduction, as observed by fluorescent intensity.
  • Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: Non-small cell lung cancer is one of the biggest killers in cancer, with squamous cell being the most difficult to treat.
  • LIfT Biosciences is a Biotech bringing to market a 1st in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT).

Vita Therapeutics Bolsters Leadership to Advance Multiple Technology Platforms

Retrieved on: 
Tuesday, March 22, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Therapy, Regenerative medicine, Quality assurance, Biomedical sciences, Biotechnology, Neurodegeneration, Champions Oncology, University of Pittsburgh School of Medicine, Technology, Knowledge, Bankers Trust, Series, GMP, University, MANA, Johns Hopkins University, IPSC, Quality, Cell engineering, CMC, Faculty, Senior, Industry, B cell, Cancer, Certification, University of Washington Department of Bioengineering, Clinical trial, Genetics, Doctor of Philosophy, ASCP, Organizational culture, Vita, Xana, Manufacturing, Health technology, MS, Trust, StemCells, Inc., Wilfrid Sellars, Patient, Company, Muscular dystrophy, Organization, Precigen, Leadership, Microbiology, Technology transfer, BS, Food, US Foods, Regulation, Mesoblast, Translational research, LGMD, Management, Pharmaceutical industry, Research

In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.

Key Points: 
  • In addition, Brown Advisory Chief Financial Officer and Chief Operating Officer David M. Churchill is newly-appointed to the Vita Therapeutics Board of Directors.
  • His leadership roles at Brown Advisory will serve our company well as he provides knowledge and perspective around our growing infrastructure.
  • Vita Therapeutics is a biotechnology company generating state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers.
  • Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.

PhenoVista Biosciences Announces Michelle Mack as VP of Business Development

Retrieved on: 
Thursday, March 3, 2022
Data Management, Health, Technology, Photography, Other Technology, Pharmaceutical, Biotechnology, Neuron, Business development, ISCB Senior Scientist Award, Champions Oncology, Crown Bioscience International, 3D, Technology, Business, Growth, Seton Hall University, Multimedia, Pfizer, Rochester Institute of Technology, CEO, 2D, Champion, General manager, Fine chemical, Management, Philosophy, Science, Biotechnology, Microbiology

PhenoVista Biosciences, a provider of imaging-based, phenotypic assay services, announces Dr. Michelle Mack as their new Vice President of Business Development.

Key Points: 
  • PhenoVista Biosciences, a provider of imaging-based, phenotypic assay services, announces Dr. Michelle Mack as their new Vice President of Business Development.
  • View the full release here: https://www.businesswire.com/news/home/20220303005391/en/
    Dr. Michelle Mack, Vice President of Business Development at PhenoVista Biosciences (Photo: Business Wire)
    At PhenoVista, Michelle will develop and implement business plans for expanding the companys drug-screening services into new regions, markets, and scientific fields.
  • I am thrilled to be joining PhenoVista at such a pivotal time in the companys history, and eager to begin developing new collaborations and strategic partnerships that will enable the expansion of PhenoVistas assay services into new therapeutic markets, said Michelle Mack, Vice President of Business Development at PhenoVista.
  • Were delighted to welcome Michelle to our growing team, says James G. Evans, CEO and co-founder of PhenoVista.

DGAP-News: Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus

Retrieved on: 
Wednesday, October 20, 2021
Clinical trial, Biotechnology, Champion, NASDAQ, Technology, MD, Medication, Growth, Proximity, NJ, Champions Oncology, Wi-Fi Direct, CEO, Industry, Fine chemical, Medical imaging, Champions Oncology, Inc., OpenZone, CHAMPIONS ONCOLOGY, INC., OPENZONE

HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan.

Key Points: 
  • HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan.
  • OpenZone is a scientific campus conceived by the healthcare company Zambon to create value in the field of Health, by fostering community, competencies, and capital.
  • With the arrival of Champions Oncology, it is home to 34 enterprises and is undergoing a substantial expansion phase.
  • "Expanding our laboratory footprint into Europe is a tremendous milestone for Champions," said Ronnie Morris, MD, CEO of Champions Oncology.

DGAP-News: Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Branches of biology, Life sciences, Medicine, Champions Oncology, Biomarker

HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space.

Key Points: 
  • HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space.
  • Specifically, Champions' scientists can establish multiple drug response datasets from the same tumor or re-interrogate these tumors with newly approved drugs or drug combinations.
  • "Drug discovery and development is the natural next step for Champions," said Michael Ritchie, PhD, MBA, Chief Commercial Officer at Champions Oncology.
  • Champions Oncology is actively engaged in the transformation of drug discovery and development of oncology therapeutics.

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

Retrieved on: 
Monday, December 10, 2018
Champions Oncology

HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ --Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018.

Key Points: 
  • HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ --Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018.
  • The company will host a conference call to discuss the second quarter results that day at 4:30 p.m. EST (1:30 p.m. PST).
  • To participate in the call, please call 877-407-8035 (domestic) or 201-689-8035 (international) ten minutes ahead of the call and give the verbal reference "Champions Oncology."
  • Champions Oncology, Inc. is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs.

Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York

Retrieved on: 
Thursday, September 13, 2018
Champions Oncology

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ --Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 onMonday, September 17th in New York.

Key Points: 
  • HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ --Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 onMonday, September 17th in New York.
  • To schedule a meeting, please contact your conference representative or James Carbonara at Hayden IR.
  • Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
  • TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business.